XASX
AVR
Market cap115mUSD
Jul 23, Last price
4.96AUD
1D
-5.21%
1Q
0.61%
Jan 2017
-86.36%
IPO
-96.98%
Name
Anteris Technologies Ltd
Chart & Performance
Profile
Anteris Technologies Ltd operates as a structural heart company. It manufactures and sells ADAPT, a regenerative tissue product. The company also engages in the developing of DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. In addition, it researches and develops regenerative medicines. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | 2016‑06 | |
Income | ||||||||||
Revenues | 4,367 6.23% | 4,111 -10.43% | 4,590 -41.08% | |||||||
Cost of revenue | 130,993 | 61,069 | 48,044 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (126,626) | (56,957) | (43,454) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (187) | (1,404) | ||||||||
Tax Rate | ||||||||||
NOPAT | (126,626) | (56,770) | (42,051) | |||||||
Net income | (123,263) 83.06% | (67,333) 51.86% | (44,340) 93.57% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 115,727 | 78,932 | 31,959 | |||||||
BB yield | -69.09% | -26.41% | -10.42% | |||||||
Debt | ||||||||||
Debt current | 1,210 | 978 | 757 | |||||||
Long-term debt | 3,291 | 3,688 | 1,298 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,312 | 1,859 | 2,072 | |||||||
Net debt | (109,338) | (26,166) | (11,750) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (98,947) | (51,433) | (38,995) | |||||||
CAPEX | (3,661) | (3,552) | (2,409) | |||||||
Cash from investing activities | (3,684) | (3,902) | (1,360) | |||||||
Cash from financing activities | 182,304 | 72,950 | 31,364 | |||||||
FCF | (128,265) | (60,080) | (44,071) | |||||||
Balance | ||||||||||
Cash | 113,839 | 30,832 | 13,805 | |||||||
Long term investments | ||||||||||
Excess cash | 113,621 | 30,626 | 13,576 | |||||||
Stockholders' equity | (464,284) | 28,662 | 13,218 | |||||||
Invested Capital | 569,124 | 4,192 | 3,478 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 20,253 | 15,606 | 13,818 | |||||||
Price | 8.27 -56.81% | 19.15 -13.74% | 22.20 71.30% | |||||||
Market cap | 167,492 -43.96% | 298,853 -2.57% | 306,750 71.30% | |||||||
EV | 58,026 | 272,747 | 295,000 | |||||||
EBITDA | (126,626) | (54,167) | (41,712) | |||||||
EV/EBITDA | ||||||||||
Interest | 430 | 967 | ||||||||
Interest/NOPBT |